Hyderabad's Tech Hub Status Grows with Major Expansions
Hyderabad is solidifying its position as a global enterprise technology hub as Sanofi more than doubled its Global Capability Centre workforce to approximately 5,000 specialists focused on R&D and AI. In parallel, Rx Propellant is investing $100 million in a new life sciences campus. The Telangana government further stated its ambition to develop a world-class "Health City" and become a global leader in integrated life sciences.
- Sanofi's Global Capability Centre (GCC) in Hyderabad, initially focused on medical services in 2019, has expanded to support R&D, digital innovation, AI, data analytics, and commercial operations globally. The recent expansion adds over 2.7 lakh square meters of workspace, making it one of the top three pharmaceutical GCCs in India. - The growth of Global Capability Centres (GCCs) in India represents a shift from back-office support to high-value innovation hubs. India is now home to over 1,700 GCCs employing more than 1.9 million people, with the market projected to reach up to $110 billion by 2030. - Rx Propellant's new 1GV campus is a 136,000 sq. ft. research and innovation facility located in Genome Valley, one of Asia's largest life sciences clusters. The campus is designed with a focus on sustainability, holding LEED Platinum and IFC EDGE Advanced Pre-Certification. - Hyderabad's Genome Valley is a major life sciences hub, hosting over 200 companies, including six of the top 10 global R&D firms like Novartis and Syngene. The cluster is a key center for drug discovery, clinical research, and large-scale pharmaceutical manufacturing. - The Telangana government's planned "Health City" is envisioned as an integrated ecosystem combining advanced medical infrastructure, research institutions, and digital health technologies. This initiative is part of a broader strategy to establish Hyderabad as a global hub for medical tourism and to create a health profile for every citizen. - Telangana's life sciences sector is currently valued at over $80 billion and is projected to reach $250 billion by 2030. The state accounts for one-third of the global vaccine supply and nearly one-third of India's total pharmaceutical production. - The growth in Hyderabad's life sciences sector has significantly impacted its real estate market, with office space leasing by life sciences companies increasing six-fold between 2022 and the first half of 2025 compared to the 2016-2019 period. - In addition to Sanofi and Rx Propellant, other major global players like Amgen, Merck Sharp & Dohme (MSD), and Miltenyi Biotec have also recently expanded their presence in Hyderabad.
